

**Ind-Swift Laboratories Limited***Registered Office*SCO 850, Shivalik Enclave,  
NAC Manimajra, Sector 13,  
Chandigarh – 160101 INDIA

✉ info@indswiftlabs.com

☎ 0172-2730503, 2730920, 5061851-53

CIN No. L24232CH1995PLC015553

**Ref: ISLL:CH:2026****Date: 27<sup>th</sup> February, 2026****The President  
Corporate Relationship Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001****The Vice President,  
Listing Compliance Department,  
National Stock Exchange of India Limited,  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/2, G-Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400 051****BSE Scrip Code: 532305****NSE Symbol: INDSWFTLAB****SUB: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Ma'am,

We have received attached intimation under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on 26<sup>th</sup> February, 2026 from M/s. Essix Biosciences Limited, regarding acquisition of 51,00,000 equity shares upon conversion of equivalent numbers of warrants into equity.

We request you to treat this intimation as compliance with the aforesaid regulations and take the same on record.

Thanking you,  
For **IND-SWIFT LABORATORIES LTD.**

**PARDEEP VERMA  
VP-CORPORATE AFFAIRS &  
COMPANY SECRETARY**

**Manufacturing Facilities:**

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu &amp; Kashmir - 184121

☎ 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiftgroup.com

Follow us:

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com

# Essix Biosciences Limited

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA)

Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294

Place of Business: Village Bhabat, Zirakpur Ambala Highway, Zirakpur, Mohali- Punjab (India)

Ph. +91-9317812731, CIN NO. U74999CH1993PLC033428

**Date: February 26, 2026**

To,  
The Listing Compliance Department  
**National Stock Exchange of India Limited,**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400051

To,  
The Listing Compliance Department,  
**BSE Limited**  
P. J. Tower, Dalal Street  
Mumbai – 400 001

**Symbol: INDSWFTLAB**

**Scrip Code: 532305**

**Subject : Disclosure under Regulation 29(2) of the Securities and Exchange Board of India  
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011.**

Dear Sir/ Madam,

With reference to the captioned note that I, Himanshu Jain on behalf of Essix Biosciences Limited (“**Acquirer**”), members of Promoter & Promoter Group of Ind-Swift Laboratories Limited (“**Target Company**”) along with Nidhi Munjal, Meenakshi Mehta, Ravi Mehta, Neeta Munjal, Himanshu Jain, Sunita Jain, Gopal Munjal, Saurabh Munjal, Rishav Mehta, V.R. Mehta, Sahil Munjal, N.R. Munjal, S. R. Mehta, Bhanavi Mehta, Ishav Mehta, Deepti Munjal, Divya Munjal, Daksh Mehta, Annie Mehta (hereinafter collectively referred to as “**PACs**”), wish to inform your good office that the Acquirer, has acquired 51,00,000 (Fifty-One Lakh) Equity Shares of face value of Rs. 10/- each of the Target Company on Tuesday, February 24, 2026, pursuant to the conversion of Fully Convertible Warrants into Equity Shares.

In this regard, please find enclosed the disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 by Essix Biosciences Limited on behalf of the whole Promoter & Promoter group of the Company.

You are requested to take the same on records.

**Thanking You.**

**Yours Faithfully,**


**For ESSIX BIOSCIENCES LIMITED**

  
**HIMANSHU JAIN**  
**DIRECTOR**

**DIN: 00014533**

**Date: February 26, 2026**

**Place: Chandigarh**



**CC:**

**The Board of Directors**

**Ind- Swift Laboratories Limited**

**SCO:850, Shivalik Enclave, NAC, Manimajra, Chandigarh-160101, India**

**Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers)**

**Regulations, 2011**

Name of the Target Company (TC)	<b>Ind- Swift Laboratories Limited</b>		
Names of the Acquirer and Persons Acting in Concert (PAC) with the Acquirer	Essix Biosciences Limited <b>("Acquirer")</b> 1. Nidhi Munjal, 2. Meenakshi Mehta, 3. Ravi Mehta, 4. Neeta Munjal, 5. Himanshu Jain, 6. Sunita Jain, 7. Gopal Munjal, 8. Saurabh Munjal, 9. Rishav Mehta, 10. V.R. Mehta, 11. Sahil Munjal, 12. N.R. Munjal, 13. S. R. Mehta, 14. Bhanavi Mehta, 15. Ishav Mehta, 16. Deepti Munjal, 17. Divya Munjal, 18. Daksh Mehta, 19. Annie Mehta <b>(Collectively referred to as "PACs")</b>		
Whether the Acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. National Stock Exchange of India Limited (" <b>NSE</b> ") and 2. BSE Limited (" <b>BSE</b> ")		
<b>Details of the acquisition as follows</b>	<b>Number</b>	<b>% w.r.t. total Share/voting capital wherever applicable</b>	<b>% w.r.t. total diluted Share/voting capital of the TC</b>
<b>Before the acquisition/disposal under consideration, holding of:</b>			
a. Shares carrying voting rights:			
<b>Acquirer:</b>			
<i>Essix Biosciences Limited</i>	2,77,82,521	34.04	29.81*
<i>PAC's</i>	44,51,757	5.45	4.78*



b. Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	Nil	NA	NA
c. Voting rights (VR) otherwise than by equity shares	Nil	NA	NA
d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category):	Nil	NA	NA
<b>Acquirer:</b> <i>Essix Biosciences Limited</i>	51,00,000	-	5.47*
<b>e. Total (a+b+c+d)</b>	<b>3,73,34,278</b>	<b>39.50</b>	<b>40.05</b>
<b>Details of acquisition</b>			
a. Shares carrying voting rights acquired/sold:-			
<b>Acquirer:</b>			
<i>Essix Biosciences Limited</i>	51,00,000	5.88	5.47
b. VRs acquired /sold otherwise than by shares	Nil	NA	NA
c. Warrants/ <del>convertible securities/any other instrument</del> that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold:	Nil	NA	NA
d. Shares encumbered/invoked/released by the acquirer	Nil	NA	NA
<b>e. Total (a+b+c+d)</b>	<b>51,00,000</b>	<b>5.88</b>	<b>5.47</b>
<b>After the acquisition, holding of:</b>			
a. Shares carrying voting rights:			
<b>Acquirer:</b>			
<i>Essix Biosciences Limited</i>	3,28,82,521	37.92	35.28
<i>PACs</i>	44,51,757	5.13	4.78
b. Shares encumbered with the acquirer	Nil	NA	NA
c. VRs otherwise than by equity shares	Nil	NA	NA
d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition:			
<b>e. Total (a+b+c+d)</b>	<b>3,73,34,278</b>	<b>43.06</b>	<b>40.05</b>
Mode of acquisition (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter se transfer etc.)	<b>Preferential Allotment</b> (Equity Shares allotted pursuant to the conversion of Fully Convertible Warrants)		



Date of receipt of intimation of allotment of shares, whichever is applicable	February 24, 2026 ("Date of Allotment")
Equity share capital / total voting capital of the TC before the said acquisition	Rs. 81,61,15,580/- divided into 8,16,11,558 Equity Shares of face value of Rs. 10/- each.
Equity share capital/ total voting capital of the TC after the said acquisition	Rs. 86,71,15,580/- divided into 8,67,11,558 Equity Shares of face value of Rs. 10/- each.
Total diluted share/voting capital of the TC after the said acquisition	Rs. 93,21,15,580/- divided into 9,32,11,558 Equity Shares of face value of Rs. 10/- each.

*\*Percentages have been calculated at Fully Diluted Pre Capital of 9,32,11,558 Securities including 8,16,11,558 Equity Shares, and 1,16,00,000 Fully Convertible Warrants.*

**For Essix Biosciences Limited**

  
  
**HIMANSHU JAIN**  
**DIRECTOR**  
**DIN: 00014533**  
**Date: February 26, 2026**  
**Place: Chandigarh**

# Essix Biosciences Limited

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA)

Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294

Place of Business: Village Bhabat, Zirakpur Ambala Highway, Zirakpur, Mohali- Punjab (India)

Ph. +91-9317812731, CIN NO. U74999CH1993PLC033428

---

**Date: February 26, 2026**

**To,**  
**Company Secretary & Compliance Officer**  
**Ind- Swift Laboratories Limited**  
SCO:850, Shivalik Enclave, NAC,  
Manimajra, Chandigarh -160101, India

**Subject: Submission of disclosure under Regulation 7(2)(a) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.**

Dear Sir/Madam,

With reference to the above-captioned subject, please note that I, Himanshu Jain on behalf of Essix Biosciences Limited, Promoter of Ind- Swift Laboratories Limited ('**the Company**') have acquired 51,00,000 Equity Shares pursuant to the conversion of fully convertible warrants of the Company having face value of Rs. 10/- each on February 24, 2026, on a preferential basis.

In reference to the above, kindly find enclosed herewith the disclosure required under Regulation 7(2)(a) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Kindly take the above information on your records.

**For Essix Biosciences Limited**

  
**HIMANSHU JAIN**  
**DIRECTOR**

**DIN: 00014533**

**Date: February 26, 2026**

**Place: Chandigarh**




**FORM C**  
**SEBI (PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015**  
**[REGULATION 7 (2) READ WITH REGULATION 6(2) – CONTINUAL DISCLOSURE]**

Name of the Company: IND- SWIFT LABORATORIES LIMITED  
 ISIN of the Company: INE915B01019

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2)

Name, PAN, CIN/DIN, & address with contact nos.	Category of Person (Promoter/member of the promoter group/designated person/Director s/immediate relative to/others etc.)	Securities held prior to acquisition/disposal		Securities acquired/Disposed				Securities held post acquisition/disposal		Date of allotment advice/ acquisition of shares/ sale of shares specify		Date of Intimation to company	Mode of acquisition / disposal (on market/public/ rights/ preferential offer / off market/Inter-se transfer, ESOPs etc.)	Exchange on which the trade was executed
		Type of securities (For e.g. – Shares, Warrants, Convertible Debentures, Rights entitlements etc.)	No. and % of shareholding	Type of securities (For e.g. – Shares, Warrants, Convertible Debentures, Rights entitlement, etc.)	No.	#Value (in Rs.)	Transaction Type (Buy/ Sale/ Pledge / Revoke/ Invoke)	Type of securities (For e.g. – Shares, Warrants, Convertible Debentures, Rights entitlement, etc.)	No. and % of Shareholding	From	To			
Name: Essix Biosciences Limited  Registered Office Address: SCO 850, Shivalik Enclave, Chandigarh-160101, India Contact No.: 0172-2730503	Promoter	Equity Shares	2,77,82,521 34.04%*	Equity Shares pursuant to the conversion of Fully Convertible Warrants	51,00,000 5.88%**	61,71,00,000 #	Buy	Equity Shares	3,28,82,521 37.92%**	Feb. 24, 2026	Feb. 24, 2026	Feb. 24, 2026	Allotment of Equity Shares pursuant to the conversion of Fully Convertible Warrants, on a Preferential basis	NA



(\*) These percentages have been calculated on the basis of the pre-issue share capital of the Company i.e. Rs. 81,61,15,580/- divided into 8,16,11,558 Equity Shares of face value of Rs. 10/- each.

(\*\*) These percentages have been calculated on the basis of the post-issue share capital of the Company i.e. Rs. 86,71,15,580/- divided into 8,67,11,558 Equity Shares of face value of Rs. 10/- each.

(#) This value has been calculated on the basis of the issue price at which allotment was made by the Company i.e. Rs. 121/- each.

**Details of trading in derivatives of the company by Promoter, Employee or Director of a listed company and other such persons as mentioned in Regulation 6(2).**

Trading in derivatives (Specify type of contract, Futures or Options etc.)						Exchange on which the trade was executed
Type of contract	Contract specifications	Buy		Sell		
		Notional Value	Number of units (contracts * lot size)	Notional Value	Number of units (contracts * lot size)	
N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

Note: In case of Options, notional value shall be calculated based on Premium plus strike price of options.

For ESSIX BIOSCIENCES LIMITED

  
HIMANSHU JAIN  
DIRECTOR

DIN: 00014533

Date: February 26, 2026

Place: Chandigarh

